KRAS and neoplasm: Excitingly, AMG510 was approved by the U.S. Food and Drug Administration, on May 28, 2021, as the first treatment for adult patients with NSCLC whose tumours harbour KRAS (G12C) mutations and who have received at least one prior systemic therapy130.